DiaMedica Therapeutics Inc. (DMAC)
| Market Cap | 157.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.57M |
| Shares Out | 16.69M |
| EPS (ttm) | -0.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $8.42 |
| Previous Close | $9.31 |
| Change ($) | -0.89 |
| Change (%) | -9.56% |
| Day's Open | 8.92 |
| Day's Range | 8.25 - 9.00 |
| Day's Volume | 259,315 |
| 52-Week Range | 2.25 - 10.30 |
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today ann...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort o...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) announced that it recently received written responses from the FDA following a Type B Pre-IND meeting request that the ...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neur...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological di...
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2020 Results - Earnings Call Transcript
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, No...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, has been invited to present at Lake Street’s 4th Annual Best Ideas Growth (BIG...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for chronic kidney disease, today announced dos...
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2020 Results - Earnings Call Transcript
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and neurological...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the closing of its previously announced underwritten registere...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its second quarter 2020 financial results will be released after the markets close on Tuesday, Aug...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today the pricing of the previously announced underwritten registere...
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, announced today that it intends to offer and sell its common shares in an unde...
DiaMedica Therapeutics (NASDAQ: DMAC) shares are trading higher on Wednesday after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $14 per share.
DiaMedica Therapeutics Inc.'s (DMAC) CEO Rick Pauls on Q1 2020 Results - Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2019 Results - Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q3 2019 Results - Earnings Call Transcript
MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rd Annual Best Ideas G...
MINNEAPOLIS, Sept. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will present at the 2019 Dougherty & Co. Institutional Investor Con...
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2019 Results - Earnings Call Transcript
Shares of the thinly traded nano-cap biotech DiaMedica Therapeutics Inc (NASDAQ: DMAC) were rallying strongly Thursday.
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2019 Results - Earnings Call Transcript
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2018 Results - Earnings Call Transcript
About DMAC
DiaMedica Therapeutics, a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company also develops ... [Read more...]
| Industry Biotechnology | Founded 2000 |
| CEO Dietrich John Pauls M.B.A., MBA | Employees 8 |
| Stock Exchange NASDAQ | Ticker Symbol DMAC |
Analyst Forecasts
According to 4 analysts, the average rating for DMAC stock is "Strong Buy." The 12-month stock price forecast is 16.20, which is an increase of 92.40% from the latest price.